SCHEMBL24733700

SCHEMBL24733700

CN(C)C(=O)[C@H](CC(=O)OC(C)(C)C)N(C)C(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.49
SYK P43405 1/20 0.41
ITGB3 P05106 1/20 0.41
ITGA2B P08514 1/20 0.41
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40
CTSS P25774 1/20 0.40
CTSK P43235 1/20 0.40
ALDH1A1 P00352 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
MAPK1 P28482 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37
KLK7 P49862 1/20 0.37
KLK5 Q9Y337 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23879129 1.00 ABCB1 (0.49) ABCB1SYKITGB3ITGA2BCTSL
SCHEMBL23879166 0.92 ABCB1 (0.48) ABCB1SYKITGB3ITGA2BCTSL
SCHEMBL27810816 0.91 ABCB1 (0.50) ABCB1SYKITGB3ITGA2BCTSL
SCHEMBL2729968 0.91 ABCB1 (0.50) ABCB1SYKITGB3ITGA2BCTSL
SCHEMBL18675299 0.90 ABCB1 (0.49) ABCB1SYKITGB3ITGA2BCTSL
SCHEMBL23879138 0.89 ABCB1 (0.57) ABCB1ITGB3ITGA2BCTSLCTSB
SCHEMBL24734869 0.86 ABCB1 (0.40) ABCB1SYKITGB3ITGA2BCTSL
SCHEMBL23879154 0.84 ABCB1 (0.52) ABCB1ITGB3ITGA2BCTSLCTSB
SCHEMBL29973797 0.84 ABCB1 (0.44) ABCB1SYKITGB3ITGA2BCTSL
SCHEMBL213307 0.84 ABCB1 (0.50) ABCB1SYKALDH1A1L3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4678652-A1 METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-01-14 EP disclosed
US-20250257094-A1 METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-08-14 US disclosed
US-20250197450-A1 METHOD FOR PRODUCING N-ALKYL AMINO ACID AND PEPTIDE INCLUDING N-ALKYL AMINO ACID CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-19 US disclosed
EP-4570813-A1 METHOD FOR PRODUCING N-SUBSTITUTED AMINO ACID RESIDUE-CONTAINING CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-18 EP disclosed
US-12312379-B2 Methods for producing cyclic compounds comprising N-substituted amino acid residues CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-05-27 US disclosed
WO-2024219480-A1 METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND 中外製薬株式会社 2024-10-24 WO disclosed
EP-4414374-A1 METHOD FOR PRODUCING N-ALKYL AMINO ACID AND PEPTIDE INCLUDING N-ALKYL AMINO ACID Chugai Seiyaku Kabushiki Kaisha (JP) 2024-08-14 EP disclosed
WO-2024080333-A1 METHOD FOR PRODUCING N-SUBSTITUTED AMINO ACID RESIDUE-CONTAINING CYCLIC PEPTIDE COMPOUND 中外製薬株式会社 2024-04-18 WO disclosed
WO-2023127869-A1 METHOD FOR PRODUCING N-ALKYL AMINO ACID AND PEPTIDE INCLUDING N-ALKYL AMINO ACID 中外製薬株式会社 2023-07-06 WO disclosed
US-20220411462-A1 METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-12-29 US disclosed
US-20220411462-A1 METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-12-29 US disclosed
WO-2022234864-A1 METHOD FOR PRODUCING CYCLIC COMPOUND CONTAINING N-SUBSTITUTED AMINO ACID RESIDUE 中外製薬株式会社 2022-11-10 WO disclosed
EP-4086272-A1 METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES Chugai Seiyaku Kabushiki Kaisha (JP) 2022-11-09 EP disclosed
EP-4086272-A1 METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES Chugai Seiyaku Kabushiki Kaisha (JP) 2022-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197450-A1 METHOD FOR PRODUCING N-ALKYL AMINO ACID AND PEPTIDE INCLUDING N-ALKYL AMINO ACID NPPA, MGMT, ANPEP ABCB1 2990/4885SYK 1826/4885ITGB3 4361/4885
US-20220411462-A1 METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES NGLY1, NPPA, VIP ABCB1 3568/4885SYK 2174/4885ITGB3 4867/4885
US-12312379-B2 Methods for producing cyclic compounds comprising N-substituted amino acid residues NGLY1, NPPA, VIP ABCB1 3568/4885SYK 2174/4885ITGB3 4867/4885
US-20250257094-A1 METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES NGLY1, NPPA, VIP ABCB1 3568/4885SYK 2174/4885ITGB3 4867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.